Methods and compositions for administration of oxybutynin

• US 8,748,488 B2
• Filed: 03/14/2013
• Issued: 06/10/2014
• Est. Priority Date: 05/30/2008
• Status: Expired due to Fees

• Current Assignee: MicroDose Therapeutx, Inc. (Teva Pharmaceutical Industries Limited)
• Original Assignee: MicroDose Therapeutx, Inc. (Teva Pharmaceutical Industries Limited)
• Inventors: Martin, Michael J., Watts, Alan B., Cook, Robert
• Primary Examiner(s): Fubara, Blessing M
• Assistant Examiner(s): Berrios, Jennifer A
• Application Number:
  US13/830,431
• Publication Number:
  US 20130267593A1
• Time in Patent Office: 453 Days
• Field of Search: 424/400, 424/489, 514/534
• US Class Current: 514/534
• CPC Class Codes: A61K 31/216 of acids having aromatic rings, e.g. benactizyne, clofibrate
• CPC Class Codes: A61K 9/0073 Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M
• CPC Class Codes: A61K 9/0075 for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 13/00 Drugs for disorders of the urinary system
• CPC Class Codes: C07C 219/20 the carbon skeleton being unsaturated
• CPC Class Codes: C07C 2601/14 The ring being saturated
• CPC Class Codes: C07C 53/124 Acids containing four carbon atoms
• CPC Class Codes: C07C 65/11 with carboxyl groups on a condensed ring system containing two rings
• CPC Class Codes: Y10T 428/2982 Particulate matter [e.g., sphere, flake, etc.]

Abstract

Administration of Oxybutynin directly to a patient'"'"'s lungs for treating urinary incontinence, respiratory disease or IBD.

Claims

1. A composition comprising oxybutynin xinofoate, and one or more pharmaceutically acceptable carriers.

2. The composition of claim 1, wherein the oxybutynin xinofoate has a defined aerodynamic particle size.

3. The composition of claim 2, wherein the aerodynamic particle size ranges between 0.1 microns to 10 microns.

4. The composition of claim 3, wherein the aerodynamic particle size ranges between 0.5 microns to 8 microns.

5. The composition of claim 3, wherein the aerodynamic particle size ranges between 0.5 microns to 6 microns.

6. The composition of claim 1, wherein the composition is in dry powder form.

7. The composition of claim 6, wherein the composition is delivered via a dry powder inhaler, a metered dose inhaler, or via nebulizer.

8. The composition of claim 6, wherein the composition is delivered in a dose of 1 to 20 mg/day.

9. The composition of claim 6, wherein the composition is delivered in a dose of 1 to 150 mg/day.